Temenos to Host SCALE Virtual Developer Conference to Shape the Future of Banking
3.11.2020 12:00:00 EET | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that registration is open for Temenos SCALE on the 17-18 November 2020. Temenos SCALE is the biggest developer conference in the banking industry, attracting developers from over 106 countries and from every type and size of institution across the banking industry. At Temenos SCALE, this global developer community will experience hands-on workshops, presentations and demonstrations with a focus on Explainable AI, microservices and open APIs and cloud technologies. Register here for this free to attend event.
Paul Roberts, Director, Temenos Developer Community & MarketPlace, Temenos, said: “Developers love Temenos because we have the most advanced technology, the richest ecosystem and the largest customer base of the most ambitious and challenger banks. We recognize the vital role our developer community plays in shaping the future of banking and we are committed to developers’ success. We invest an industry leading 20 per cent of our revenues into research and development – a further $1bn investment over just the next few years. And we are making significant investment in our developers too, supporting them with the tools, skills and knowledge to use our technology to solve real world problems at scale. Our API-first technology and modern microservices-based architecture enables rapid innovation and our MarketPlace gives developers a shop window into banks serving more than one billion people around the world. Banking truly is the most exciting space for developers right now and Temenos SCALE is the flagship event to bring the developer community together, to learn, share and grow.”
Attendees of Temenos SCALE will hear from influential technology and banking industry leaders. Temenos CEO Max Chuard will keynote on why now is a pivotal moment in the banking industry, how developers are shaping the future and making banking a force for good and how Temenos is supporting them with innovative technologies to create and bring new products to market faster.
Banks face mounting pressure as they try to keep pace with evolving customer expectations, competition and changing regulations. Covid-19 has accelerated the shift to digital banking and SaaS; Open Banking regulation is splitting the value chain and proving a catalyst for innovation; and with the rise of big tech, customers now expect seamless, hyper-personalized experiences. These trends are driven and enabled by technology and banks increasingly need developers to help them survive and thrive in this digital-first era.
The Temenos SCALE event will include over 40 sessions, including hands-on workshops and product demonstrations. Attendees will also hear from Temenos’ technology partners and customers. ABN AMRO will share insights on the power of analytics, Openbank on the extensibility of Temenos Transact to differentiate and Canadian Western Bank on design thinking. The event is supported by IBM as the headline sponsor, Microsoft, Red Hat, TailWind, NuoDB and Syncordis,
Andre Tost, Distinguished Engineer and CTO, IBM Cloud Pak Architecture, said: “At Temenos SCALE, you’ll hear about how IBM and our business partner Temenos are working together to bring hybrid cloud solutions to banking, and deliver greater automation, innovation and integration capabilities to our joint clients. I hope you’ll join us as we explore the incredible advances of modern software and API-led technology built with IBM offerings, like LinuxONE and IBM Cloud Paks. We look forward to engaging the brightest minds in the developer community – today’s change leaders – to discuss how we can work together to create powerful change in the banking industry on a global scale.”
Follow #TemenosSCALE on social media for live updates on LinkedIn, Twitter, Facebook and Instagram.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201103005032/en/
Contact information
Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email : press@temenos.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom